Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
BJU International
|
May 14, 2016
The small renal mass. Where is the wisdom we have lost in knowledge? Where is the knowledge we have lost in information?
Michael Aitchison, Maxine Tran
The Journal of Urology
|
November 11, 2005
Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy
Sara Ramsey, Michael Aitchison
Nature Clinical Practice. Urology
|
February 14, 2006
Is histologic subtype a significant prognostic factor in renal cell carcinoma?
Sara Ramsey, Michael Aitchison
BJU International
|
April 29, 2006
A case for screening for renal cancer
Sara Ramsey, Michael Aitchison
Nature Clinical Practice. Urology
|
September 12, 2006
Treatment for renal cancer: are we beyond the cytokine era?
Sara Ramsey, Michael Aitchison
BJU International
|
March 14, 2008
The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer
Sara Ramsey, Michael Aitchison, John Graham, et al.
BMJ (Clinical Research Ed.)
|
July 28, 2011
Sexual dysfunction in cardiovascular disease
Deborah Morrison, Michael Aitchison, Derek T Connelly, et al.
International Urology and Nephrology
|
December 20, 2005
Case report: octreotide as an adjunct to embolisation in the management of recurrent bleeding upper gastrointestinal metastases from primary renal cell cancer
Gavin W A Lamb, Jon Moss, Richard Edwards, et al.
Current Urology
|
June 12, 2014
The epidemiology and risk factors for renal cancer
Tahir Qayyum, Grenville Oades, Paul Horgan, et al.
Acta Oncologica (Stockholm, Sweden)
|
March 25, 2005
Concurrent presentation of stage I teratoma and stage I renal cell cancer
Jeff D White, Morag M Seywright, Michael Aitchison, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
BJU International
|
May 14, 2016
The small renal mass. Where is the wisdom we have lost in knowledge? Where is the knowledge we have lost in information?
Michael Aitchison, Maxine Tran
The Journal of Urology
|
November 11, 2005
Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy
Sara Ramsey, Michael Aitchison
Nature Clinical Practice. Urology
|
February 14, 2006
Is histologic subtype a significant prognostic factor in renal cell carcinoma?
Sara Ramsey, Michael Aitchison
BJU International
|
April 29, 2006
A case for screening for renal cancer
Sara Ramsey, Michael Aitchison
Nature Clinical Practice. Urology
|
September 12, 2006
Treatment for renal cancer: are we beyond the cytokine era?
Sara Ramsey, Michael Aitchison
BJU International
|
March 14, 2008
The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer
Sara Ramsey, Michael Aitchison, John Graham, et al.
BMJ (Clinical Research Ed.)
|
July 28, 2011
Sexual dysfunction in cardiovascular disease
Deborah Morrison, Michael Aitchison, Derek T Connelly, et al.
International Urology and Nephrology
|
December 20, 2005
Case report: octreotide as an adjunct to embolisation in the management of recurrent bleeding upper gastrointestinal metastases from primary renal cell cancer
Gavin W A Lamb, Jon Moss, Richard Edwards, et al.
Current Urology
|
June 12, 2014
The epidemiology and risk factors for renal cancer
Tahir Qayyum, Grenville Oades, Paul Horgan, et al.
Acta Oncologica (Stockholm, Sweden)
|
March 25, 2005
Concurrent presentation of stage I teratoma and stage I renal cell cancer
Jeff D White, Morag M Seywright, Michael Aitchison, et al.
Page
of 4